Roche Not Ruling Out Creative Deals For ‘Tail End’ Brands
Executive Summary
A better value proposition and more in-tune marketing ideas would drive a more creative risk-sharing or asset swap-like arrangement for the oncology specialist’s more mature brands, says Roche CEO Severin Schwan.
You may also be interested in...
Sanofi Off-Patent Brands In Deal Hunter Lupin’s Sights?
Indian drug maker Lupin is openly scouting for global deals. While it is being seen as a possible bidder for some GSK generic brands, experts say the company may also be involved in examining several other similar transactions.
Emerging Markets Earnings Roundup: Roche (Part 7)
Roche’s international growth in pharmaceuticals was a modest 2% in the second quarter, a likely reason for a generally subdued earnings call. But the tone was upbeat on the second half with a few clues offered on M&A strategy.
Alzheimer’s R&D In Brief: Roche’s Crenezumab Misses Endpoints, Novartis Plans Large New Genetic Study
In data presented at the Alzheimer's Association International Conference in Copenhagen, held July 12-17, Roche’s anti-amyloid beta antibody misses endpoints in two Phase II studies, but there were some promising signs of efficacy.